![download dm network viewer version1.5 download dm network viewer version1.5](https://video.informer.com/frames/f118172285349238.frame.jpg)
Additionally, according to a multicenter, prospective, randomized controlled trial for patients with COVID-19, LHQW-C could ameliorate the efficiency of clinical treatment, shorten the time of fever, cough, and fatigue, improve chest CT findings, and accelerate the recovery of COVID-19 patients. Among the Diagnosis and Treatment of Novel Coronavirus Pneumonia (Version 4/Version 5/Version 6/Version 7) issued by China's National Health Commission, LHQW-C was recommended as one of the basic TCM for the treatment of COVID-19.Ī retrospective and observational study demonstrated that LHQW-C could improve patient clinical symptoms, including fever, cough, chest tightness, and decreased appetite.
![download dm network viewer version1.5 download dm network viewer version1.5](https://img.informer.com/screenshots/720/720504_1.jpg)
Wu Jutong in Qing dynasty, mainly prescribed in the treatment of colds, pneumonia. MXSGT, a notable classic formula recorded in Shanghan Lun edited by Zhang Zhongjing in Han Dynasty, is mainly prescribed for the treatments of febrile diseases, including influenza, acute bronchitis, and pneumonia. Lianhuaqingwen capsule (LHQW-C), a Chinese patent medicine contains 13 medicinal herbs ( Fructus Forsythiae, Flos Lonicerae Japonicae, Herba Ephedrae, Almond, Radix Isatidis, Fortunes Boss fern Rhizome, Herba Houttuyniae, Herba Pogostemonis, Rheum palmatum, Rhodiola rosea, Glycyrrhiza uralensis Fisch, Mentha haplocalyx Briq and Gypsum Fibrosum) is derived from two classics prescriptions: Ma Xing Shi Gan Tang (MXSGT) and Yin Qiao San (YQS). So far, no vaccines or specific drugs have been found for COVID-19, and the primary treatments are supportive. More seriously, infected individuals can develop pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and even death. Among these COVID-19 patients, common symptoms include fever, cough, myalgia, and dyspnea. As of 14 April 2020, over 1,700,000 cases were confirmed with 100,000 deaths over 100 countries worldwide. In December 2019, a severe respiratory disease (COVID-19) was identified in China, which is caused by a new virus, SARS-CoV-2. Keywords: Lianhuaqingwen capsule, COVID-19, 3CL pro, SARS-CoV-2, network pharmacology IntroductionĬoronaviruses are enveloped RNA viruses, of which the pandemic causes a serious threat to humans and evolved into public health events. The study indicates that some anti-inflammatory ingredients in LHQW-C probably modulate the inflammatory response in severely ill patients with COVID-19. Moreover, four key components (quercetin, luteolin, wogonin, and kaempferol) showed a high binding affinity with SARS-CoV-2 3-chymotrypsin-like protease (3CL pro). KEGG enrichment analysis indicated that the targets of LHQW-C were highly enriched to several immune response-related and inflammation-related pathways, including the IL-17 signaling pathway, TNF signaling pathway, NF-kappa B signaling pathway, and Th17 cell differentiation. GO function analysis revealed that these targets were associated with inflammatory response, oxidative stress reaction, and other biological processes. Finally, 158 active ingredients in LHQW-C were screen out, and 49 targets were predicted. In this study, an integrating network pharmacology approach including pharmacokinetic screening, target prediction (targets of the host and targets from the SARS-CoV-2), network analysis, GO enrichment analysis, KEGG pathway enrichment analysis, and virtual docking were conducted.
![download dm network viewer version1.5 download dm network viewer version1.5](https://iiif.elifesciences.org/lax:63377%2Felife-63377-fig7-v2.tif/full/,1500/0/default.jpg)
However, the active ingredients, drug targets, and the therapeutic mechanisms of LHQW-C in treating COVID-19 are poorly understood. Lianhuaqingwen capsule (LHQW-C), a traditional Chinese medicine (TCM) formula widely used for respiratory diseases, shows therapeutic efficacy in the application of coronavirus disease 2019 (COVID-19). The outbreak of severe respiratory disease caused by SARS-CoV-2 has led to millions of infections and raised global health concerns. Select the file that you have just downloaded and select import option Reference Manager (RIS).
#Download dm network viewer version1.5 download#
Available fromĬlick on Go to download the file. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19. Zhang X, Gao R, Zhou Z, Tang X, Lin J, Wang L, Zhou X, Shen T.